Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Written by Customer Service on February 28, 2024. Posted in Earnings Releases And Operating Results.

Achieved Record 2023 Total Revenues of $398.2 Million, an 85.9% Increase Compared to 2022 Achieved Record Fourth Quarter 2023 Total Revenues of $110.6 Million, an 82.0% Increase Compared to Fourth Quarter 2022 Reported 2023 GAAP Net Income of $71.4 Million, $0.63 Per Share Diluted Reported 2023 Non-GAAP Net Income of $223.2 Million, $1.96 Per Share Diluted Bolstered Neuroscience Commercial Portfolio with the FDA Approval of AGAMREE® Commercial Launch of AGAMREE on Track for Q1 2024 Full Year 2024 Total Revenues Guidance of Between $455 Million and $475 Million Conference Call and Webcast to be Held on February 29, 2024, at 8:30 AM ET CORAL GABLES, Fla., Feb. 28, 2024 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX) today reported financial results for the fourth...

The Saikyo Bank Partners with nCino to Enhance Operational Efficiency and Customer-Centric Services

Written by Customer Service on February 28, 2024. Posted in Public Companies.

Japanese regional bank selects nCino to create a customer-driven mortgage lending experience by streamlining processes and systems onto a single platform TOKYO, Feb. 28, 2024 (GLOBE NEWSWIRE) — nCino, Inc. (NASDAQ: NCNO), a pioneer in cloud banking for the global financial services industry, today announced that The Saikyo Bank, Ltd. (Saikyo), a $20B-asset regional bank in Japan, will implement nCino to improve operational efficiencies and customer convenience. Saikyo will start its single platform journey with nCino by introducing the technology to its mortgage operations. The adoption of nCino’s platform aims to streamline Saikyo’s mortgage business, from reception, screening, case management and electronic contracting to the execution of mortgage loan operations, allowing the Bank to improve efficiency and customer...

Intchains Announces Closing of Acquisition of Goldshell Brand-related Assets

Written by Customer Service on February 28, 2024. Posted in Public Companies.

SHANGHAI, China, Feb. 28, 2024 (GLOBE NEWSWIRE) — Intchains Group Limited (Nasdaq: ICG) (“Intchains,” “we,” or the “Company”), a provider of integrated solutions consisting of high-performance computing ASIC chip products and ancillary software and hardware for blockchain applications, today announced that it has completed its previously reported acquisition of certain assets from Singapore-based GOLDSHELL PTE. LTD. (the “Seller”), pursuant to an asset acquisition agreement (the “Asset Acquisition Agreement”) entered between the Company and the Seller dated December 8, 2023 (the “Transaction”). Pursuant to the terms and conditions of the Asset Acquisition Agreement, we acquired all the intellectual property, information and technical materials used in operating the Goldshell brand, which primarily include (i) all trademarks and...

DallasNews Corporation Announces Schedule for Fourth Quarter and Full Year 2023 Financial Results Release and Conference Call

Written by Customer Service on February 28, 2024. Posted in Public Companies.

DALLAS, Feb. 28, 2024 (GLOBE NEWSWIRE) — DallasNews Corporation (Nasdaq: DALN) said today that it will release fourth quarter and full year 2023 financial results before the market opens on Thursday, March 7, 2024. A conference call will be held on Thursday, March 7, 2024 at 9:00 a.m. CST. The conference call will be simultaneously webcast on DallasNews Corporation’s website at investor.dallasnewscorporation.com/events. An archive of the webcast will be available at dallasnewscorporation.com in the Investor Relations section. To access the listen-only conference call, dial 1-844-291-6362 and enter the following access code when prompted: 4561809. A replay line will be available at 1-866-207-1041 from 12:00 p.m. CST on March 7, 2024 until 11:59 p.m. CDT on March 13, 2024. The access code for the replay is 8115710. About DallasNews...

Intchains Group Limited Reports Fourth Quarter and Full Year 2023 Unaudited Financial Results

Written by Customer Service on February 28, 2024. Posted in Public Companies.

SHANGHAI, China, Feb. 28, 2024 (GLOBE NEWSWIRE) — Intchains Group Limited (Nasdaq: ICG) (“we,” or the “Company”), a provider of integrated solutions consisting of high-performance computing ASIC chip products and ancillary software and hardware for blockchain applications, today announced its unaudited financial results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter 2023 Operating and Financial Highlights Sales volume of ASIC chips was 423,040 units for the fourth quarter of 2023, representing a decrease of 36.5% from 666,420 units for the same period of 2022. Fourth quarter ASIC chip sales consisted of 287,872 units sold directly to customers and 135,168 units embedded in computing equipment for blockchain applications that we began offering to customers in the fourth quarter of 2023. Revenue was...

Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023

Written by Customer Service on February 28, 2024. Posted in Earnings Releases And Operating Results.

NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an operational update and reported financial results for the period ended December 31, 2023. Mesoblast Chief Executive Silviu Itescu said: “We were very busy operationally during the last quarter and continued to have positive engagement with the United States Food and Drug Administration (FDA) across our lead programs. We have strengthened our balance sheet while maintaining overall spending constraint in line with our corporate objectives. For our product Ryoncil® (remestemcel-L) for life-threatening steroid-refractory acute graft-versus-host disease (SR-aGVHD) ahead of our upcoming meeting in March we have provided the FDA with new data from a second potency...

Opthea Reports Half-Year Financial Results and Business Updates

Written by Customer Service on February 28, 2024. Posted in Earnings Releases And Operating Results.

Enrollment completion of sozinibercept Phase 3 program for wet AMD expected in calendar year (CY) Q2 2024 with top-line data mid-CY 2025 Expanded U.S. leadership team with the appointments of Dr. Frederic Guerard as CEO, Peter Lang as CFO, and Dr. Arshad M. Khanani as Chief Medical Advisor Cash and cash equivalents of $157.1 million as of December 31, 2023 MELBOURNE, Australia and PRINCETON, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) — Opthea Limited (ASX:OPT; NASDAQ:OPT; “Opthea”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced financial results for the six months ended December 31, 2023 and highlighted recent corporate and clinical updates. “It is a transformative time for Opthea. We substantially advanced the development of sozinibercept,...

Stantec announces record 2023 earnings, dividend increase of 7.7%, and planned retirement of CFO Theresa Jang

Written by Customer Service on February 28, 2024. Posted in Earnings Releases And Operating Results.

2023 Highlights Net revenue of $5.1 billion in 2023, an increase of 13.7% over 2022 Adjusted diluted EPS1 of $3.67, an increase of 17.3% over 2022 Backlog of $6.3 billion, up 6.8% since December 31, 2022 Ranked #9 of the most sustainable corporations in the world by Corporate Knights, first among peers EDMONTON, Alberta and NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) — TSX, NYSE:STN Stantec, a global leader in sustainable design and engineering, today reported its results for the fourth quarter and year ended December 31, 2023. Stantec achieved record financial results and delivered another solid year of excellent performance in 2023. Net revenue increased $609 million to $5.1 billion, driven primarily by 9.9% organic growth1 and 1.5% acquisition growth1. Continued focus on strong project execution and operational excellence drove...

Vow ASA: Full year and second half of 2023 results

Written by Customer Service on February 28, 2024. Posted in Earnings Releases And Operating Results.

Oslo, 28 February 2024: Vow ASA (OSE: VOW) revenues for the full year 2023 were NOK 918.5 million, a 17 per cent increase from the year before. EBITDA before non-recurring items was negative NOK 23.4 million for the full year. In addition, the company recorded non-recurring items of negative NOK 31.3 million, mainly related to non-cash balance sheet clean-up in contract accruals. This resulted in a negative EBITDA for the year of NOK 54.7 million versus a positive NOK 85.5 million in 2022. “The year 2023 was a year of high activity and revenue. A large number of projects were successfully delivered. Activity in aftersales was increasing. We also secured important new contracts and moved into position for new projects in new industry verticals,” said Henrik Badin, CEO of Vow ASA. At the end of 2023, the order backlog was NOK 1 034 million...

Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update

Written by Customer Service on February 28, 2024. Posted in Earnings Releases And Operating Results.

Company focused on adenosine platform clinical development WESTPORT, Conn., Feb. 28, 2024 (GLOBE NEWSWIRE) — Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported financial results for the fiscal quarter ended December 31, 2023. “The Company is focused on advancing its ADPORT-201 Phase 1a/1b clinical trial of PORT-6 (adenosine 2A inhibitor) and PORT-7 (adenosine 2B inhibitor) in selected solid tumors. The trial is progressing well with eight academic center clinical sites enrolling patients. The Phase 1a dose escalation portion of the trial has progressed to the third cohort. The Company looks forward to making a clinical update at the 2024 American Society of Clinical Oncology...

Day: February 28, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice